Your browser doesn't support javascript.
loading
Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma.
Ferrone, Cristina; Goyal, Lipika; Qadan, Motaz; Gervais, Debra; Sahani, Dushyant V; Zhu, Andrew X; Hong, Theodore S; Blaszkowsky, Lawrence S; Tanabe, Kenneth K; Vangel, Mark; Amorim, Barbara J; Wo, Jennifer Y; Mahmood, Umar; Pandharipande, Pari V; Catana, Ciprian; Duenas, Virginia P; Collazo, Yolanda Q; Canamaque, Lina G; Domachevsky, Liran; Bernstine, Hanna H; Groshar, David; Shih, Tiffany Tsing-Fang; Li, Yan; Herrmann, Ken; Umutlu, Lale; Rosen, Bruce R; Catalano, Onofrio A.
Affiliation
  • Ferrone C; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Goyal L; Department of Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Qadan M; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Gervais D; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
  • Sahani DV; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
  • Zhu AX; Department of Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Hong TS; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Blaszkowsky LS; Department of Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Tanabe KK; Department of Oncology, Newton-Wellesley Hospital, 2114 Washington St., Newton, MA, 02462, USA.
  • Vangel M; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Amorim BJ; Department of Biostatics, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Wo JY; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
  • Mahmood U; Division of Nuclear Medicine, State University of Campinas (UNICAMP), Campinas, Brazil.
  • Pandharipande PV; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
  • Catana C; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
  • Duenas VP; Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, 149 13th, Charlestown, MA, 02129, USA.
  • Collazo YQ; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
  • Canamaque LG; Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, 149 13th, Charlestown, MA, 02129, USA.
  • Domachevsky L; Department of Nuclear Medicine and Radiology, Hospital HM Puerta del Sur, Avda Carlos V 70, 28938, Madrid, Spain.
  • Bernstine HH; Department of Surgery, Hospital HM Sanchinarro, Avda Carlos V 70, 28938, Madrid, Spain.
  • Groshar D; Department of Nuclear Medicine and Radiology, Hospital HM Puerta del Sur, Avda Carlos V 70, 28938, Madrid, Spain.
  • Shih TT; Department of Radiology and Nuclear Medicine, Assuta Medical Center, HaBarzel St. 20, Tel Aviv-Yafo, Israel.
  • Li Y; Department of Radiology and Nuclear Medicine, Assuta Medical Center, HaBarzel St. 20, Tel Aviv-Yafo, Israel.
  • Herrmann K; Department of Radiology and Nuclear Medicine, Assuta Medical Center, HaBarzel St. 20, Tel Aviv-Yafo, Israel.
  • Umutlu L; Department of Medical Imaging and Radiology, National Taiwan University College of Medicine and Hospital, No. 7, Chung-Shan South Rd., Taipei, 10016, Taiwan.
  • Rosen BR; Department of Radiology, Universitatsklinikum, Essen University, Hufelandstraße 55, 45147, Essen, Germany.
  • Catalano OA; Department of Nuclear Medicine, Universitatsklinikum, Essen University, Hufelandstraße 55, 45147, Essen, Germany.
Eur J Nucl Med Mol Imaging ; 47(8): 1871-1884, 2020 07.
Article in En | MEDLINE | ID: mdl-31705172
ABSTRACT

PURPOSE:

Intrahepatic cholangiocarcinoma (ICC) is associated with a poor prognosis with surgical resection offering the best chance for long-term survival and potential cure. However, in up to 36% of patients who undergo surgery, more extensive disease is found at time of operation requiring cancellation of surgery. PET/MR is a novel hybrid technology that might improve local and whole-body staging in ICC patients, potentially influencing clinical management. This study was aimed to investigate the possible management implications of PET/MR, relative to conventional imaging, in patients affected by untreated intrahepatic cholangiocarcinoma.

METHODS:

Retrospective review of the clinicopathologic features of 37 patients with iCCC, who underwent PET/MR between September 2015 and August 2018, was performed to investigate the management implications that PET/MR had exerted on the affected patients, relative to conventional imaging.

RESULTS:

Of the 37 patients enrolled, median age 63.5 years, 20 (54%) were female. The same day PET/CT was performed in 26 patients. All patients were iCCC-treatment-naïve. Conventional imaging obtained as part of routine clinical care demonstrated early-stage resectable disease for 15 patients and advanced stage disease beyond the scope of surgical resection for 22. PET/MR modified the clinical management of 11/37 (29.7%) patients for 5 patients (13.5%), the operation was cancelled due to identification of additional disease, while 4 "inoperable" patients (10.8%) underwent an operation. An additional 2 patients (5.4%) had a significant change in their operative plan based on PET/MR.

CONCLUSIONS:

When compared with standard imaging, PET/MR significantly influenced the treatment plan in 29.7% of patients with iCCC. TRIAL REGISTRATION 2018P001334.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Bile Duct Neoplasms / Cholangiocarcinoma Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Bile Duct Neoplasms / Cholangiocarcinoma Type of study: Observational_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Year: 2020 Type: Article